Posts

Showing posts with the label personalized medicine market

Genomic Technologies, Government Initiatives, and Heightened Public Awareness Propel the Global Market for Personalized Medicine

Image
A new study by Industry Experts, Inc., on " Personalized Medicine " has been published. Global Personalized Medicine market is estimated at US$531.7 billion in 2024 and projected to post a CAGR of 8.5% between 2024 and 2030 to reach US$869.9 billion by 2030. The global market for personalized medicine is driven by several significant factors, such as advancements in genomic technologies, increased public awareness, and supportive government initiatives for personalized healthcare. Innovations in technologies like Next-Generation Sequencing (NGS), artificial intelligence (AI), machine learning (ML), liquid biopsy, and nanotechnology are revolutionizing personalized medicine by enabling more accurate and effective therapies. Additionally, an increase in clinical trials, innovations in pharmacogenomics, and the expansion of genetic databases are contributing to the market's growth. As healthcare continues to move toward a more individualized approach, the person...

Personalized Medicine Global Market to Reach nearly $200 Billion by 2024, Owing to Huge Patient Data Availability, Advanced Analytics and Customized Medicine - Market Report (2017-2024) by Industry Experts, Inc.

Image
Industry Experts, Inc. released the updated version of its global market report on Personalized Medicine. The new report entitled " Global Personalized Medicine Market – Types, Technologies and Applications " reveals that the global market for Personalized Medicine is forecast to touch US$102.7 billion in 2018. Personalized medicine has a huge potential in leading the healthcare industry with drastic changes with a key focus on diseases understanding & management integrated with advanced analytics, patient data, customized medicines and other possibilities. Personalized Medicine will transform the entire pharmaceutical value chain, from early development to companies' go-to-market models, and the next five years will be a crucial window for pharmaceutical companies to capitalize on this promise. Companies simply cannot sit on the sidelines during this period. Instead, they need to take risks and more actively engage with stakeholders throughout the healthcare ecosy...